Abliva AB Stock Deutsche Boerse AG
Stocks
NTP
SE0002575340
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Deutsche Boerse AG
12:23:40 17/03/2025 +04
|
5-day change | 1st Jan Change | ||
| 0.0373 EUR | +23.92% |
|
-.--% | - |
| 17/03/25 | Calendar Monday, March 17 | FW |
| 17/03/25 | Abliva has today the last trading day on Nasdaq Stockholm before delisting | FW |
| 1 day | +23.92% |
| 3 years | 0 |  | 0.04 |
| 5 years | 0 | | 0.06 |
| 10 years | 0 | | 0.73 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 59 | 10/01/2014 | |
Dag Nesse
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/02/2023 |
Magnus Hansson
CTO | Chief Tech/Sci/R&D Officer | 50 | 01/01/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 72 | 06/11/2017 | |
| Director/Board Member | 66 | 27/04/2017 | |
David Bejker
BRD | Director/Board Member | 51 | 27/04/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +23.92% | -.--% | - | - | 76M | |
| -1.79% | -2.27% | +50.90% | +89.03% | 67.98B | |
| -2.06% | -0.18% | +41.53% | +88.17% | 64.94B | |
| -0.31% | +6.54% | -11.39% | +457.82% | 27.58B | |
| -3.00% | -2.90% | +39.40% | +9.41% | 25.74B | |
| +0.86% | +1.65% | +0.25% | -14.78% | 26.06B | |
| -1.46% | +0.42% | +24.07% | -18.70% | 20.09B | |
| -2.96% | -15.21% | +210.71% | +370.84% | 17.16B | |
| -1.49% | -4.88% | -0.41% | +530.26% | 14.92B | |
| -0.20% | +8.37% | +57.87% | +159.50% | 14.62B | |
| Average | +1.15% | +0.26% | +45.88% | +185.73% | 31.01B | |
| Weighted average by Cap. | -1.51% | +0.18% | +42.29% | +145.08% |
Employees
6
- Stock Market
- Stocks
- ABLI Stock
- NTP Stock
Select your edition
All financial news and data tailored to specific country editions
